Connetics chronicles

Connetics chronicles

Connetics (CNCT), which last week agreed to be acquired by Stiefel for about $640 million in cash, has seen two big stock runs abruptly cut short when setbacks prompted investors to bail out of the dermatology play. Since its IPO in 1996, CNCT's strategy has been to in-license products that have been displaced after strategic reorganization of large drug companies and to

Read the full 647 word article

How to gain access

Continue reading with a
two-week free trial.